Medikamentöse Therapie der Colitis ulcerosa

  • Guido Adler

Zusammenfassung

Die Colitis ulcerosa ist durch keine konservative Maßnahme zu heilen. Die medikamentöse Therapie hat das Ziel, durch Verringerung der Entzündungsaktivität die Symptomatik zu verbessern, die Lebensqualität des Patienten zu steigern und das Auftreten von Rezidiven zu verhindern. Die Wahl der Therapie muß sich dabei an der Krankheitsaktivität und dem Vorhandensein von Komplikationen orientieren. Darüber hinaus wird die therapeutische Strategie von der Lokalisation und der Ausdehnung der Entzündung beeinflußt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adler DJ, Korelitz BI (1990) The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 85:717–722PubMedGoogle Scholar
  2. Baron JH, Connell PM, Lennard-Jones JE et al. (1962) Sulphasalazine and salicylazonsulphadimidine in ulcerative colitis. Lancet I:1094–1096CrossRefGoogle Scholar
  3. Burke DA Axon ATR, Clayden SA et al. (1990) The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Therap 4:123–129CrossRefGoogle Scholar
  4. Campieri M, De Franchis R, Bianchi Porro G et al. (1990) Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis, Scan J Gastroenterol 25:663–668CrossRefGoogle Scholar
  5. Campieri M, Gionchetti P, Belluzzi A et al. (1991) Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 31:929–931CrossRefGoogle Scholar
  6. Collawn C, Rubin P, Perez N et al. (1992) Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis. Am J Gastroenterol 87:342–436PubMedGoogle Scholar
  7. Danish 5-ASA Group (1987) Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. Dig Dis Sci 32:598–602CrossRefGoogle Scholar
  8. Danielsson Å, Löfberg R, Persson T et al. (1992) Asteroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 27:9–12PubMedCrossRefGoogle Scholar
  9. Ginsberg AL, Beck LS, McIntosh TM et al. (1988) Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas: A double-blind, placebo-controlled trial. Ann Intern Med 108:195–199PubMedGoogle Scholar
  10. Järnerot G, Rolny P, Sandberg-Gertzen H (1985) Intensive intravenous treatment of ulcerative colitis. Gastroenterology 89:1005–1013PubMedGoogle Scholar
  11. Laursen LS, Naesdal J, Bukhave K et al. (1990) Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet 335:683–684PubMedCrossRefGoogle Scholar
  12. Lennard-Jones JE, Longmore AJ, Newel AC et al. (1960) An assessment of prednisone, salazopyrine, and topical hydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut 1:217–222PubMedCrossRefGoogle Scholar
  13. Levine DS, Fischer SH, Christie DL et al. (1992) Intrevenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn’s colitis. Am J Gastroenterol 87:91–100PubMedGoogle Scholar
  14. Lichtiger S, Present DH (1990) Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 336:16–19PubMedCrossRefGoogle Scholar
  15. Meyers S, Sachar DB, Goldberg JD et al. (1983) Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial. Gastroenterology 85:351–357PubMedGoogle Scholar
  16. Meyers S, Sachar DB, Present DH et al. (1987) Olsalazine sodium in the treatment of ulcerative colitis among patients intoleran of sulfasalazine. Gastroenterology 93:1255–1262PubMedGoogle Scholar
  17. Miner PB Jr, Biddle WL (1990) Maintaining remission in distal ulcerative colitis and ulcerative proctitis. Can J Gastroenterol 4:476–480Google Scholar
  18. Rachmilewitz D (International study group) (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 298:82–86CrossRefGoogle Scholar
  19. Ruddell WSJ, Dickinson RJ, Dixon MF et al. (1980) Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocortisone enemas and rectal hydrocortisone foam. Gut 21:885–889PubMedCrossRefGoogle Scholar
  20. Rutgeerts P (1989) Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Aliment Pharmacol Therap 3:183–191CrossRefGoogle Scholar
  21. Salomon P, Kronbluth AA, Janowith HD (1990) Treatment of ulcerative colitis with fish oil n-3-ω-fatty acid: an open trial. J Clin Gastroenterol 12:157–161PubMedCrossRefGoogle Scholar
  22. Scheppach W, Sommer H, Kirchner T et al. (1992) Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 103:51–56PubMedGoogle Scholar
  23. Sninsky CA, Cort DH, Shanahan F et al. (1991) Oral mesalamine (asacol) for mildly to moderatly active ulcerative colitis. Ann Intern Med 115:350–355PubMedGoogle Scholar
  24. Sutherland LR, Robinson M, Onstad G et al. (1990) A double-blind, placebo controlled, multicentre study of the efficacy and safety of 5-aminosalicyl acid tablets on the treatment of ulcerative colitis. Can J Gastroenterol 4:463–467Google Scholar
  25. Sutherland LR, Martin F, Greer S et al. (1987) 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92:1894–1898PubMedGoogle Scholar
  26. Suzuki R, Toda H, Takamura Y (1989) Dynamics of blood coagulation factor XIII in ulcerative colitis and preliminary study of the factor XIII concentrate. Blut 59:162–164PubMedCrossRefGoogle Scholar
  27. Truelove SC, Witts LJ (1955) Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 2:1041–1048PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • Guido Adler
    • 1
  1. 1.Medizinische Klinik und PoliklinikUniversität UlmUlmDeutschland

Personalised recommendations